# Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients

> **NCT06395285** · PHASE1 · RECRUITING · sponsor: **Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)** · enrollment: 12 (estimated)

## Conditions studied

- ROSAH

## Interventions

- **DRUG:** DF-003

## Key facts

- **NCT ID:** NCT06395285
- **Lead sponsor:** Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-27
- **Primary completion:** 2026-02
- **Final completion:** 2026-05
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06395285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06395285, "Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06395285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*